16th Annual Heart Failure Holiday Symposium
Implications of New HF Therapies on HF Guidelines: Is the SGLT2i Drug Class a Breakthrough Therapy for Prevention and Treatment of HF? Can MRA, ARB and ARNi Be Used in HFpEF Patients?
By
16th Annual Heart Failure Holiday Symposium
FEATURING
Clyde Yancy
By
16th Annual Heart Failure Holiday Symposium
FEATURING
Clyde Yancy
Login to view comments.
Click here to Login
